Fukuda Denshi (6960) Q2 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2027 earnings summary
30 Oct, 2026Executive summary
H1 FY2027 revenue was ¥64,688m, down 0.2% YoY; operating income fell 0.9%, while ordinary income rose 0.4%.
Attributable net income declined 4.2% to ¥7,263m; full-year guidance was unchanged, with sales growth forecast alongside lower operating and net income.
Financial highlights
Revenue was ¥64,688m; gross profit ¥35,154m, operating income ¥10,563m, ordinary income ¥10,974m and net income ¥7,263m.
Gross profit decreased from ¥35,476m YoY; selling, general and administrative expenses declined to ¥24,591m from ¥24,813m.
Comprehensive income increased 19.2% YoY to ¥11,131m, including a ¥4,109m gain in other securities valuation differences.
Outlook and guidance
FY2027 guidance remains unchanged: revenue ¥142,000m (+1.6% YoY), operating income ¥25,500m (-4.2%), net income ¥17,700m (-5.8%) and EPS ¥654.37.
Sales are typically strongest in Q4, making reasonable half-year estimates difficult; no Q2 earnings forecast is issued.
Latest events from Fukuda Denshi
- First-quarter profits and comprehensive income rose sharply, with guidance reaffirmed.6960
Q1 2027 - Modest sales and profit growth, with FY2027 guidance signaling lower earnings and a compliance incident.6960
Q4 2026 - Slight YoY profit decline offset by strong comprehensive income and stable full-year outlook.6960
Q3 2026 - Net sales up 0.8% and operating profit steady, with segment shifts and stable full-year outlook.6960
Q2 2026 - Sales rose 4% year-over-year, but profits declined; full-year guidance and dividends unchanged.6960
Q1 2025 - First-half profits fell on lower sales, but full-year guidance and dividend plans remain unchanged.6960
Q2 2025 - Profits declined despite stable sales, with mixed segment performance and steady full-year outlook.6960
Q3 2025 - Slight declines in sales and profit, with FY2026 guidance indicating further contraction.6960
Q4 2025 - Profits declined despite stable sales; medical treatment and consumables segments showed growth.6960
Q1 2026